# Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management

Study · id `cardio:ct-nct01584557` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01584557](<https://clinicaltrials.gov/study/NCT01584557>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01584557

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.

## Technical summary

Registry record NCT01584557. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2016-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 250 participants (enrolled count; ClinicalTrials.gov record NCT01584557, source copy `cardio:ctgov-nct01584557-2016-09-27`, retrieved 2026-10-26)
- Start date: 2012-06 (registry gives no type) (ClinicalTrials.gov record NCT01584557, source copy `cardio:ctgov-nct01584557-2016-09-27`, retrieved 2026-10-26)
- Primary completion: 2016-07 (actual) (ClinicalTrials.gov record NCT01584557, source copy `cardio:ctgov-nct01584557-2016-09-27`, retrieved 2026-10-26)
- Completion: 2016-08 (actual) (ClinicalTrials.gov record NCT01584557, source copy `cardio:ctgov-nct01584557-2016-09-27`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01584557, source copy `cardio:ctgov-nct01584557-2016-09-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01584557-2016-09-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management
- Acronym: Secret of CHF
- Condition: Heart Failure
- Intervention (Drug): Tolvaptan or Samsca
- Intervention (Drug): placebo or sugar pill
- Lead sponsor: Cardiovascular Clinical Sciences Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload (`cardio:pubmed-28302292`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c1c88b1c5ab39ebe68626c39ab6ddff76d2caa26a51e9023049d1534fc10c1cc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
